Research
Hormonal
Co-agonism of the glucagon and GLP-1 receptors improves glycemia in people with diabetes and obesity.
Practitioners may consider glucagon and GLP-1 receptor co-agonists as a treatment option for improving glycemia.
StrongSupportsmedium confidence
Co-agonism of the glucagon and glucagon-like peptide-1 (GLP-1) receptors has emerged as a promising strategy to improve glycemia in people with diabetes and obesity.
Why this rating
The claim is based on emerging strategies supported by research.
Source
Glucagon-based therapy for people with diabetes and obesity: What is the sweet spot?
Emma Rose McGlone et al. · Peptides · 2024
otherCited 8×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →